No evidence of association between human cytomegalovirus infection and papillary thyroid cancer

World Journal of Surgical Oncology

Shih-Ping Cheng²  Jie-Jen Lee²  Tung-Sun Huang¹ 

[1] Department of Surgery, Mackay Medical College and Mackay Memorial Hospital, No. 92, Sec 2, Chung-Shan North Road, Taipei 10449, Taiwan;Department of Pharmacology and Graduate Institute of Medical Sciences, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 11031, Taiwan

关键词: Papillary thyroid cancer;    BRAF;    Cytomegalovirus;   

Others  :  820326
DOI  :  10.1186/1477-7819-12-41

 received in 2013-10-17, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

Human cytomegalovirus (CMV) has been detected in the thyroid gland and thyroid tumors. CMV infection may activate the mitogen-activated protein kinase pathway, of which aberrant activation is frequently associated with BRAF mutation in papillary thyroid cancer.

Methods

A total of 45 paired tumorous and adjacent non-neoplastic tissue samples, including 5 follicular adenoma and 40 papillary thyroid cancer, were obtained during thyroidectomy. BRAF mutational status was determined using direct sequencing. The presence of CMV DNA was determined using conventional PCR and quantitative real-time PCR. CMV protein in the tissue samples were evaluated with Western blot analysis.

Results

BRAF mutation was identified in the cancerous part of 31 (78%) papillary thyroid cancers. Papillary cancer with BRAF mutation was significantly associated with a larger tumor size (P = 0.045), extrathyroidal invasion (P = 0.012), lymph node metastasis (P = 0.008), and a higher TNM stage (P = 0.044). CMV DNA and protein were not detected in any studied samples.

Conclusions

Our results suggest no association between CMV infection and papillary thyroid cancer.

【 授权许可】

   
2014 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013, 13:184-199.
• [2]Vriens MR, Suh I, Moses W, Kebebew E: Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid 2009, 19:1343-1349.
• [3]Dal Maso L, Bosetti C, La Vecchia C, Franceschi S: Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009, 20:75-86.
• [4]Caronia LM, Phay JE, Shah MH: Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011, 17:7511-7517.
• [5]Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005, 115:1068-1081.
• [6]Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP: Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013, 107:493-497.
• [7]Griffiths PD: Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis 2012, 12:790-798.
• [8]Cannon MJ, Schmid DS, Hyde TB: Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010, 20:202-213.
• [9]Soderberg-Naucler C: HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008, 41:218-223.
• [10]Johnsen JI, Baryawno N, Soderberg-Naucler C: Is human cytomegalovirus a target in cancer therapy? Oncotarget 2011, 2:1329-1338.
• [11]Reeves MB, Breidenstein A, Compton T: Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci USA 2012, 109:588-593.
• [12]Tsai JH, Tsai CH, Cheng MH, Lin SJ, Xu FL, Yang CC: Association of viral factors with non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid tumor tissues. J Med Virol 2005, 75:276-281.
• [13]Chen T, Hudnall SD: Anatomical mapping of human herpesvirus reservoirs of infection. Mod Pathol 2006, 19:726-737.
• [14]Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF: Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol 2012, 86:854-864.
• [15]Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ: Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys 2013, 65:203-210.
• [16]Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
• [17]Guarino V, Castellone MD, Avilla E, Melillo RM: Thyroid cancer and inflammation. Mol Cell Endocrinol 2010, 321:94-102.
• [18]Ye ZQ, Gu DN, Hu HY, Zhou YL, Hu XQ, Zhang XH: Hashimoto’s thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer. World J Surg Oncol 2013, 11:56. BioMed Central Full Text
• [19]Liu CL, Cheng SP, Lin HW, Lai YL: Risk of thyroid cancer in patients with thyroiditis: a population-based cohort study. Ann Surg Oncol 2014, 21:843-849.
• [20]Thomas D, Liakos V, Michou V, Kapranos N, Kaltsas G, Tsilivakos V, Tsatsoulis A: Detection of herpes virus DNA in post-operative thyroid tissue specimens of patients with autoimmune thyroid disease. Exp Clin Endocrinol Diabetes 2008, 116:35-39.
• [21]Mori K, Yoshida K: Viral infection in induction of Hashimoto’s thyroiditis: a key player or just a bystander? Curr Opin Endocrinol Diabetes Obes 2010, 17:418-424.
• [22]Jensen K, Patel A, Larin A, Hoperia V, Saji M, Bauer A, Yim K, Hemming V, Vasko V: Human herpes simplex viruses in benign and malignant thyroid tumours. J Pathol 2010, 221:193-200.
• [23]Adamson LA, Fowler LJ, Clare-Salzler MJ, Hobbs JA: Parvovirus B19 infection in Hashimoto’s thyroiditis, papillary thyroid carcinoma, and anaplastic thyroid carcinoma. Thyroid 2011, 21:411-417.
• [24]Michaelis M, Paulus C, Loschmann N, Dauth S, Stange E, Doerr HW, Nevels M, Cinatl J Jr: The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci 2011, 68:1079-1090.
• [25]Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A: Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) 2013, 78:760-767.
• [26]Kim YS, Kim JS, Bae JS, Park WC: Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol 2013, 11:99. BioMed Central Full Text
• [27]Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, Kim SJ, Hwangbo Y, Park S, Cho HD, Oh MH, Yang SH, Kim CJ: BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol 2013, 20:759-766.
• [28]Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA: Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab 2013, 98:3702-3712.
• [29]Hendrix RM, Wagenaar M, Slobbe RL, Bruggeman CA: Widespread presence of cytomegalovirus DNA in tissues of healthy trauma victims. J Clin Pathol 1997, 50:59-63.